First Trust Advisors’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-18,372
| Closed | -$464K | – | 2549 |
|
|
2024
Q4 | $464K | Sell |
18,372
-19,071
| -51% | -$482K | ﹤0.01% | 2274 |
|
|
2024
Q3 | $1.27M | Sell |
37,443
-40,293
| -52% | -$1.37M | ﹤0.01% | 1943 |
|
|
2024
Q2 | $2.88M | Buy |
77,736
+7,841
| +11% | +$290K | ﹤0.01% | 1538 |
|
|
2024
Q1 | $2.93M | Buy |
69,895
+58,332
| +504% | +$2.45M | ﹤0.01% | 1565 |
|
|
2023
Q4 | $459K | Buy |
+11,563
| New | +$459K | ﹤0.01% | 2160 |
|
|
2023
Q2 | – | Sell |
-53,072
| Closed | -$1.91M | – | 2361 |
|
|
2023
Q1 | $1.91M | Buy |
+53,072
| New | +$1.91M | ﹤0.01% | 1701 |
|
|
2022
Q4 | – | Sell |
-10,399
| Closed | -$292K | – | 2443 |
|
|
2022
Q3 | $292K | Buy |
10,399
+440
| +4% | +$12.4K | ﹤0.01% | 2331 |
|
|
2022
Q2 | $268K | Sell |
9,959
-42,814
| -81% | -$1.15M | ﹤0.01% | 2327 |
|
|
2022
Q1 | $1.8M | Sell |
52,773
-49,010
| -48% | -$1.67M | ﹤0.01% | 1813 |
|
|
2021
Q4 | $3.93M | Buy |
+101,783
| New | +$3.93M | ﹤0.01% | 1486 |
|
|
2016
Q2 | – | Sell |
-2,735,140
| Closed | -$10.3M | – | 2297 |
|
|
2016
Q1 | $10.3M | Sell |
2,735,140
-4,689,280
| -63% | -$17.7M | 0.03% | 643 |
|
|
2015
Q4 | $116M | Buy |
7,424,420
+2,614,533
| +54% | +$41M | 0.3% | 61 |
|
|
2015
Q3 | $50.7M | Buy |
4,809,887
+467,502
| +11% | +$4.93M | 0.15% | 145 |
|
|
2015
Q2 | $110M | Sell |
4,342,385
-394,558
| -8% | -$9.95M | 0.28% | 76 |
|
|
2015
Q1 | $132M | Buy |
+4,736,943
| New | +$132M | 0.39% | 36 |
|